HN2008001191A - Compuestos de biciclolactama sustituida - Google Patents

Compuestos de biciclolactama sustituida

Info

Publication number
HN2008001191A
HN2008001191A HN2008001191A HN2008001191A HN2008001191A HN 2008001191 A HN2008001191 A HN 2008001191A HN 2008001191 A HN2008001191 A HN 2008001191A HN 2008001191 A HN2008001191 A HN 2008001191A HN 2008001191 A HN2008001191 A HN 2008001191A
Authority
HN
Honduras
Prior art keywords
bicycolactam
substituted
compounds
same
bicyclolactama
Prior art date
Application number
HN2008001191A
Other languages
English (en)
Inventor
Lee Dow Robert
John Munchhof Michael
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2008001191A publication Critical patent/HN2008001191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

ESTA INVENCION SE REFIERE A DERIVADOSO DE BICICLOLACTAMA SUSTITUIDA, FORMULACIONES FARMACEUTICAS DE LA MISMA Y USOS DE LA MISMA.
HN2008001191A 2007-08-02 2008-07-29 Compuestos de biciclolactama sustituida HN2008001191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02

Publications (1)

Publication Number Publication Date
HN2008001191A true HN2008001191A (es) 2012-01-17

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001191A HN2008001191A (es) 2007-08-02 2008-07-29 Compuestos de biciclolactama sustituida

Country Status (34)

Country Link
US (2) US20090036425A1 (es)
EP (1) EP2185567B1 (es)
JP (1) JP4629808B2 (es)
KR (1) KR20100032443A (es)
CN (1) CN101772504A (es)
AP (1) AP2010005163A0 (es)
AR (1) AR067780A1 (es)
AT (1) ATE502948T1 (es)
AU (1) AU2008281545B2 (es)
BR (1) BRPI0815067A2 (es)
CA (1) CA2695291C (es)
CL (1) CL2008002227A1 (es)
CO (1) CO6251365A2 (es)
CR (1) CR11223A (es)
CY (1) CY1111628T1 (es)
DE (1) DE602008005757D1 (es)
DK (1) DK2185567T3 (es)
DO (1) DOP2010000046A (es)
EA (1) EA201000050A1 (es)
EC (1) ECSP109932A (es)
ES (1) ES2361716T3 (es)
HN (1) HN2008001191A (es)
HR (1) HRP20110335T1 (es)
MA (1) MA31580B1 (es)
PA (1) PA8791601A1 (es)
PE (1) PE20090897A1 (es)
PL (1) PL2185567T3 (es)
PT (1) PT2185567E (es)
SI (1) SI2185567T1 (es)
TN (1) TN2010000053A1 (es)
TW (1) TWI356059B (es)
UA (1) UA94833C2 (es)
WO (1) WO2009016462A2 (es)
ZA (1) ZA201000255B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
SI2402317T1 (sl) 2006-03-31 2013-10-30 Novartis Ag DGAT inhibitor
AU2007266796B2 (en) 2006-05-30 2011-02-10 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
JP5203360B2 (ja) 2006-06-23 2013-06-05 アボット・ラボラトリーズ ヒスタミンｈ３受容体調節剤としてのシクロプロピルアミン誘導体
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2010086820A1 (en) * 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2010089685A1 (en) * 2009-02-03 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
JP2012516885A (ja) * 2009-02-04 2012-07-26 ファイザー・インク ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体
WO2010108051A2 (en) 2009-03-20 2010-09-23 Ligand Pharmaceuticals Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
HUE025774T2 (en) 2010-03-19 2016-05-30 Pfizer 2,3-Dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
RU2540337C2 (ru) 2010-10-29 2015-02-10 Пфайзер Инк. N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
WO2012112364A1 (en) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
WO2012122075A1 (en) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
PL2699576T3 (pl) 2011-04-22 2016-05-31 Pfizer Pochodne pirazolospiroketonu do zastosowania jako inhibitory karboksylazy acetylo-COA
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8859536B2 (en) * 2011-05-20 2014-10-14 Glaxosmithkline Intellectual Property (No.2) Limited Compounds as diacylglycerol acyltransferase inhibitors
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013068439A1 (en) * 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
UA108713C2 (xx) 2011-11-11 2015-05-25 2-тіопіримідинони
CN104245696A (zh) * 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
MA37385B1 (fr) 2012-04-06 2019-09-30 Pfizer Inc Etat De Delaware Inhibiteurs de diacylglycérol-acyltransférase 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
RU2014147220A (ru) * 2012-04-25 2016-06-10 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новое бета-аланиновое производное, его фармацевтически приемлемые соли и фармацевтическая композиция, включающая его в качестве активного ингредиента
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
AU2013279510A1 (en) 2012-06-20 2014-10-16 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as LPAR antagonists
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
NZ630436A (en) * 2012-11-23 2016-08-26 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (en) * 2013-03-15 2014-09-18 Intervet International B.V. Pyridine derivatives as dgat-1 inhibitors
CN104418866B (zh) 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
WO2015052610A1 (en) 2013-10-09 2015-04-16 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
AP2016009407A0 (en) 2014-03-17 2016-08-31 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
SG11201608110WA (en) 2014-04-04 2016-10-28 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
MX2017014128A (es) 2015-05-05 2018-03-15 Pfizer 2-tiopirimidinonas.
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
EP3310784B1 (en) 2015-06-17 2020-10-07 Pfizer Inc Tricyclic compounds and their use as phosphodiesterase inhibitors.
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
BR112018002071A2 (pt) 2015-08-13 2018-09-18 Pfizer compostos heteroarílicos ou arílicos fundidos bicíclicos
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
JP2019524716A (ja) 2016-07-14 2019-09-05 ファイザー・インク バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
CA3140972A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2020261144A1 (en) 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995153B2 (en) 2002-01-18 2006-02-07 Kyorin Pharmaceutical. Co., Ltd. Fused bicyclic pyrimidine derivatives
MXPA05005425A (es) * 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
AU2005209115A1 (en) * 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
WO2007071966A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors

Also Published As

Publication number Publication date
CL2008002227A1 (es) 2009-04-17
WO2009016462A3 (en) 2009-03-26
TN2010000053A1 (fr) 2011-09-26
CY1111628T1 (el) 2015-10-07
PL2185567T3 (pl) 2011-07-29
CR11223A (es) 2010-02-04
TW200916471A (en) 2009-04-16
BRPI0815067A2 (pt) 2015-02-10
PT2185567E (pt) 2011-05-27
ES2361716T3 (es) 2011-06-21
AP2010005163A0 (en) 2010-02-28
ECSP109932A (es) 2010-03-31
CN101772504A (zh) 2010-07-07
ATE502948T1 (de) 2011-04-15
EP2185567A2 (en) 2010-05-19
AU2008281545A1 (en) 2009-02-05
JP4629808B2 (ja) 2011-02-09
UA94833C2 (en) 2011-06-10
US20090137551A1 (en) 2009-05-28
MA31580B1 (fr) 2010-08-02
PE20090897A1 (es) 2009-08-06
DOP2010000046A (es) 2010-03-31
ZA201000255B (en) 2011-03-30
CA2695291C (en) 2012-04-17
WO2009016462A2 (en) 2009-02-05
US20090036425A1 (en) 2009-02-05
KR20100032443A (ko) 2010-03-25
EP2185567B1 (en) 2011-03-23
CA2695291A1 (en) 2009-02-05
AR067780A1 (es) 2009-10-21
DE602008005757D1 (de) 2011-05-05
DK2185567T3 (da) 2011-05-16
SI2185567T1 (sl) 2011-06-30
TWI356059B (en) 2012-01-11
US7718645B2 (en) 2010-05-18
JP2010535190A (ja) 2010-11-18
HRP20110335T1 (hr) 2011-06-30
AU2008281545B2 (en) 2011-12-08
PA8791601A1 (es) 2009-12-16
EA201000050A1 (ru) 2010-08-30
CO6251365A2 (es) 2011-02-21

Similar Documents

Publication Publication Date Title
HN2008001191A (es) Compuestos de biciclolactama sustituida
CR10328A (es) Compuestos organicos
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
PA8774501A1 (es) Nueva sales y sus usos
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
AR059194A1 (es) Formas de dosificacion resistentes a la manipulacion
BRPI0820381A2 (pt) Formulações farmacêuticas
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
DK2139494T3 (da) Farmaceutiske formuleringer, der indeholder dapagliflozin-propylenglycolhydrat
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
HN2011003195A (es) Modulares de gpr 119
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
PA8667201A1 (es) Nuevos compuestos farmaceuticos
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина